

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal

Voxelotor for treating haemolytic anaemia in people with sickle cell disease [ID1403]

Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Global Blood Therapeutics (voxelotor) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> Action for Sick Children AOFAC Foundation African Caribbean Leukaemia Trust Blood UK Black Health Agency for Equality Cianna's Smile Contact a Family Equalities National Council Gene People Genetic Alliance UK National Children's Bureau Pain UK Sickle Cell and Young Stroke Survivors Sickle Cell Society SickleKan South Asian Health Foundation Specialised Healthcare Alliance UK Thalassaemia Society <p><u>Professional groups</u></p> <ul style="list-style-type: none"> Association of Genetic Nurses & Counsellors British Blood Transfusion Society British Committee for Standards in Haematology British Geriatrics Society British Society for Gene and Cell Therapy British Society for Genetic Medicine British Society for Haematology British Society for Human Genetics Immunodeficiency UK 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Cell and Gene Therapy Catapult Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Hospital Information Services – Jehovah's Witnesses Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee <p><u>Possible Comparator companies</u></p> <ul style="list-style-type: none"> AAH Pharmaceuticals (hydroxycarbamide) Alliance Healthcare (hydroxycarbamide) Bristol-Myers Squibb (hydroxycarbamide) Masters Pharmaceuticals (hydroxycarbamide) Medac GmbH (hydroxycarbamide) Medihealth (hydroxycarbamide) Nova Laboratories (hydroxycarbamide) Phoenix Healthcare Distribution (hydroxycarbamide)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Neonatal and Paediatric Pharmacists Group • NHS Blood and Transplant • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics and Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Forum on Haemoglobin Disorders • UK Genetic Testing Network • United Kingdom National Screening Committee <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS East Staffordshire CCG • NHS England • NHS Greenwich CCG • Welsh Government 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Cystic Fibrosis & Genetic Disorders Group • Cochrane Haematological Malignancies Group • Cochrane UK • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the stakeholder list and which organisations, we should include who have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are; companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.